DDInter127 DDInter1294
Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginase from _E. coli_ has clinically shown to exhibit antitumor actions in models of leukaemias [A31996, A31997]. L-asparaginase of _E. coli_ is marketed under several different trade names, including Elspar, for the treatment of acute lymphoblastic leukemia (ALL) as part of a multi-agent chemotherapeutic regimen. It is available as intramuscular or intravenous injections. Therapeutic L-asparaginase from _E. coli_ works by depleting the levels
Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.
Asparaginase Escherichia coli {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bicalutamide
Bicalutamide {u} (Compound) resembles {v} (Compound) Enzalutamide
Enzalutamide {u} (Compound) resembles {v} (Compound) Nilutamide
Asparaginase Escherichia coli {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enzalutamide
Enzalutamide {u} (Compound) resembles {v} (Compound) Nilutamide
Asparaginase Escherichia coli {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bicalutamide
Bicalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nitisinone
Nitisinone {u} (Compound) resembles {v} (Compound) Nilutamide
Asparaginase Escherichia coli {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Polatuzumab vedotin
Polatuzumab vedotin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enzalutamide
Enzalutamide {u} (Compound) resembles {v} (Compound) Nilutamide
Asparaginase Escherichia coli {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bicalutamide
Bicalutamide {u} (Compound) treats {v} (Disease) prostate cancer
prostate cancer {u} (Disease) is treated by {v} (Compound) Nilutamide
Asparaginase Escherichia coli {u} may lead to a major life threatening interaction when taken with {v} Teriflunomide
Teriflunomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enzalutamide
Enzalutamide {u} (Compound) resembles {v} (Compound) Nilutamide
Asparaginase Escherichia coli {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sulfamethoxazole
Sulfamethoxazole {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Nilutamide
Asparaginase Escherichia coli {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nefazodone
Nefazodone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enzalutamide
Enzalutamide {u} (Compound) resembles {v} (Compound) Nilutamide
Asparaginase Escherichia coli {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sulfamethoxazole
Sulfamethoxazole {u} (Compound) causes {v} (Side Effect) Insomnia
Insomnia {u} (Side Effect) is caused by {v} (Compound) Nilutamide
Asparaginase Escherichia coli {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bicalutamide
Bicalutamide {u} (Compound) is included by {v} (Pharmacologic Class) Androgen Receptor Antagonists
Androgen Receptor Antagonists {u} (Pharmacologic Class) includes {v} (Compound) Nilutamide
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound) and Enzalutamide (Compound) resembles Nilutamide (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Enzalutamide and Enzalutamide (Compound) resembles Nilutamide (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Nitisinone and Nitisinone (Compound) resembles Nilutamide (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedotin and Polatuzumab vedotin may cause a minor interaction that can limit clinical effects when taken with Enzalutamide and Enzalutamide (Compound) resembles Nilutamide (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) treats prostate cancer (Disease) and prostate cancer (Disease) is treated by Nilutamide (Compound)
Asparaginase Escherichia coli may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide (Compound) resembles Nilutamide (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Nilutamide (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Nefazodone and Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide (Compound) resembles Nilutamide (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Nilutamide (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) is included by Androgen Receptor Antagonists (Pharmacologic Class) and Androgen Receptor Antagonists (Pharmacologic Class) includes Nilutamide (Compound)